Owing to the rising prevalence of diseases, soaring government and non-government initiatives and policies, and surging healthcare expenditure, the adoption of single-cell analysis is predicted to rise in the coming years. The escalating healthcare expenditure, especially in the developed nations, is resulting in a huge rise in the incorporation of single-cell analysis procedures and products, such as consumables and instruments. Moreover, single-cell genomics in disease analysis allows for better personalized treatment procedures that involve the tracking, monitoring, and treatment of patients according to their individual needs.